Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.
The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.
"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment," Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.
The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.
Blueprint Medicines shares were up nearly 10% in recent trading.
Price: 95.82, Change: +8.39, Percent Change: +9.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.